K Srivastava1, T Zhang, N Yang, H Sampson, X M Li. 1. Department of Pediatrics, Division of Allergy & Immunology, The Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029-6574, USA.
Abstract
BACKGROUND: Chronic allergic asthma is the result of a T-helper type 2 (Th2)-biased immune status. Current asthma therapies control symptoms in some patients, but a long-lasting therapy has not been established. Anti-Asthma Simplified Herbal Medicine Intervention (ASHMI™), a Chinese herbal formula, improved symptoms and lung function, and reduced Th2 responses in a controlled trial of patients with persistent moderate to severe asthma. OBJECTIVE: We evaluated the persistence of ASHMI™ beneficial effects following therapy in a murine model of chronic asthma and the immunological mechanisms underlying such effects. Methods BALB/c mice sensitized intraperitoneally with ovalbumin (OVA) received 3 weekly intratracheal OVA challenges to induce airway hyper-reactivity (AHR) and inflammation (OVA mice). Additionally, OVA mice were treated with ASHMI™ (OVA/ASHMI™) or water (OVA/sham) for 4 weeks, and then challenged immediately and 8 weeks post-therapy. In other experiments, OVA mice received ASHMI™ treatment with concomitant neutralization of IFN-γ or TGF-β. Effects on airway responses, cytokine- and OVA-specific IgE levels were determined 8 weeks post-therapy. RESULTS: Before treatment, OVA mice exhibited AHR and pulmonary eosinophilic inflammation following OVA challenge, which was almost completely resolved immediately after completing treatment with ASHMI™ and did not re-occur following OVA re-challenge up to 8 weeks post-therapy. Decreased allergen-specific IgE and Th2 cytokine levels, and increased IFN-γ levels also persisted at least 8 weeks post-therapy. ASHMI™ effects were eliminated by the neutralization of IFN-γ, but not TGF-β, during therapy. CONCLUSION: ASHMI™ induced long-lasting post-therapy tolerance to antigen-induced inflammation and AHR. IFN-γ is a critical factor in ASHMI™ effects.
BACKGROUND:Chronic allergic asthma is the result of a T-helper type 2 (Th2)-biased immune status. Current asthma therapies control symptoms in some patients, but a long-lasting therapy has not been established. Anti-Asthma Simplified Herbal Medicine Intervention (ASHMI™), a Chinese herbal formula, improved symptoms and lung function, and reduced Th2 responses in a controlled trial of patients with persistent moderate to severe asthma. OBJECTIVE: We evaluated the persistence of ASHMI™ beneficial effects following therapy in a murine model of chronic asthma and the immunological mechanisms underlying such effects. Methods BALB/c mice sensitized intraperitoneally with ovalbumin (OVA) received 3 weekly intratracheal OVA challenges to induce airway hyper-reactivity (AHR) and inflammation (OVAmice). Additionally, OVAmice were treated with ASHMI™ (OVA/ASHMI™) or water (OVA/sham) for 4 weeks, and then challenged immediately and 8 weeks post-therapy. In other experiments, OVAmice received ASHMI™ treatment with concomitant neutralization of IFN-γ or TGF-β. Effects on airway responses, cytokine- and OVA-specific IgE levels were determined 8 weeks post-therapy. RESULTS: Before treatment, OVAmice exhibited AHR and pulmonary eosinophilic inflammation following OVA challenge, which was almost completely resolved immediately after completing treatment with ASHMI™ and did not re-occur following OVA re-challenge up to 8 weeks post-therapy. Decreased allergen-specific IgE and Th2 cytokine levels, and increased IFN-γ levels also persisted at least 8 weeks post-therapy. ASHMI™ effects were eliminated by the neutralization of IFN-γ, but not TGF-β, during therapy. CONCLUSION: ASHMI™ induced long-lasting post-therapy tolerance to antigen-induced inflammation and AHR. IFN-γ is a critical factor in ASHMI™ effects.
Authors: S S Saini; D W MacGlashan; S A Sterbinsky; A Togias; D C Adelman; L M Lichtenstein; B S Bochner Journal: J Immunol Date: 1999-05-01 Impact factor: 5.422
Authors: M Boguniewicz; R J Martin; D Martin; U Gibson; A Celniker; M Williams; D Y Leung Journal: J Allergy Clin Immunol Date: 1995-01 Impact factor: 10.793
Authors: Mario Castro; Sharon R Bloch; Michelle V Jenkerson; Steve DeMartino; Daniel L Hamilos; Rebecca B Cochran; Xueping E Liang Zhang; Haochuan Wang; Joseph P Bradley; Kenneth B Schechtman; Michael J Holtzman Journal: Am J Respir Crit Care Med Date: 2004-01-15 Impact factor: 21.405
Authors: Kamal Srivastava; Ariel A Teper; Teng-Fei Zhang; Side Li; Martin J Walsh; Chih-Kang Huang; Meyer Kattan; Brian H Schofield; Hugh A Sampson; Xiu-Min Li Journal: J Allergy Clin Immunol Date: 2004-02 Impact factor: 10.793
Authors: M Mathur; K Herrmann; X Li; Y Qin; J Weinstock; D Elliott; J Monahan; P Padrid Journal: Am J Respir Crit Care Med Date: 1999-02 Impact factor: 21.405
Authors: Ryan E Wiley; Monika Cwiartka; David Alvarez; David C Mackenzie; Jill R Johnson; Susanna Goncharova; Lennart Lundblad; Manel Jordana Journal: J Immunol Date: 2004-04-15 Impact factor: 5.422
Authors: Kamal D Srivastava; David Dunkin; Changda Liu; Nan Yang; Rachel L Miller; Hugh A Sampson; Xiu-Min Li Journal: Ann Allergy Asthma Immunol Date: 2014-04 Impact factor: 6.347
Authors: Kamal Srivastava; Hugh A Sampson; Charles W Emala; Xiu-Min Li Journal: Am J Physiol Lung Cell Mol Physiol Date: 2013-10-25 Impact factor: 5.464